☆ 4.6 Article

PARP inhibitor olaparib is safe and effective in patients with BRCA1 and BRCA2 mutations

Nature Reviews Clinical Oncology (2010)

Journal

Nature Reviews Clinical Oncology

Volume 7, Issue 10, Pages 549-549

Publisher

Springer Nature

DOI: 10.1038/nrclinonc.2010.143

Keywords

-

Categories

Oncology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

No Data Available

No Data Available

No Data Available

© Peeref 2019-2024. All rights reserved.